Aripiprazole in bipolar depression: A pooled, post-hoc analysis by severity of core depressive symptoms

International Journal of Psychiatry in Clinical Practice

Volumn 16, Issue 2, 2012, Pages 121-131

  Thase, Michael E ^a   Bowden, Charles L ^b   Nashat, Michael ^c   Eudicone, James M ^d   Marcus, Ronald ^d   McQuade, Robert D ^e   Carlson, Berit X ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Prince Theodore Group of Pharmacies   (Canada)

^d BRISTOL MYERS SQUIBB   (United States)

^e OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Aripiprazole; Bipolar depression; Bipolar disorder; Efficacy; Tolerability

Indexed keywords

ARIPIPRAZOLE; PLACEBO;

ADULT; AGED; AGITATION; AKATHISIA; ANXIETY; ARTICLE; ATTENTION DISTURBANCE; BACKACHE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MUSCLE TWITCH; NAUSEA; POST HOC ANALYSIS; PRIORITY JOURNAL; RESTLESSNESS; RHINOPHARYNGITIS; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AKATHISIA, DRUG-INDUCED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BODY WEIGHT; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NAUSEA; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860844540     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2011.632680     Document Type: Article

References (32)

1. Post RM. The impact of bipolar depression. J Clin Psychiatry 2005;66(Suppl 5):5-10
2. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006;163(2):217-24
3. Rosa AR, Reinares M, Michalak EE, Bonnin CM, Sole B, Franco C, et al. Functional impairment and disability across mood states in bipolar disorder. Value Health 2010;13(8): 984-8
4. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Mö ller H-J, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biolo Psychiatry 2010;11(2):81-109
5. Zornberg G, Pope HGJ. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993;13(6):397-408
6. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20(6):607-14
7. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry 2002;3(3):115-24
8. Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 2004;65(12):1715-9
9. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A randomized, double-blind, placebocontrolled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162(7):1351-60
10. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from fi ve randomised trials. Br J Psychiatry 2009;194(1):4-9
11. Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. CNS Drugs 2009;23(5):397-418
12. Young A, McElroy S, Bauer M, Philips N, Chang W, Olausson B, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010;71(2):150-62.
13. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. Effi cacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26(6):600-9
14. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28(1):13-20
15. Tohen M, Vieta E, Calabrese J, Ketter T, Sachs G, Bowden C, et al. Effi cacy of olanzapine and olanzapine-fl uoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60(11):1079 - 88.
16. Erratum in: Arch Gen Psychiatry 2004;61(2):176
17. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999;60(2):79-88
18. Kemp DE, Calabrese JR, Eudicone JM, Ganocy S, Tran QV, McQuade RD, et al. Predictive value of early improvement in bipolar depression trials: A post-hoc pooled analysis of two 8-week aripiprazole studies. Psychopharmacol Bull 2010;43(2):5-27
19. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. The effi cacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68(6):843-53
20. Berman R, Fava M, Thase M, Swanink R, McQuade R, Carson W, et al. Aripiprazole augmentation in major depression: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectrums 2009;14(4):197-206
21. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The effi cacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28(2):156-65
22. Kilts CD, Wade AG, Andersen HF, Schlaepfer TE. Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opin Pharmacother 2009; 10(6):927-36
23. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG. Quantitative rating of depressive states. Acta Psychiatr Scand 1975;51(3):161-70
24. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
25. Bech P, Tanghoj P, Andersen HF, Overo K. Citalopram doseresponse revisited using an alternative psychometric approach to evaluate clinical effects of four fi xed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berlin) 2002;163(1):20-5
26. Bech P. Rating scales in depression: limitations and pitfalls. Dialogues Clin Neurosci 2006;8(2):207-15
27. Carmody TJ, Rush AJ, Bernstein I, Warden D, Brannan S, Burnham D, et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006;16(8):601-11
28. Stein D, Baldwin D, Dolberg O, Despiegel N, Bandelow B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 2006;67(11): 1741-6
29. Goldberg JF, Perlis RH, Bowden CL, Thase ME, Miklowitz DJ, Marangell LB, et al. Manic symptoms during depres - sive episodes in 1,380 patients with bipolar disorder: fi ndings from the STEP-BD. Am J Psychiatry 2009;166(2): 173-81
30. Swann AC, Gerard Moeller F, Steinberg JL, Schneider L, Barratt ES, Dougherty DM. Manic symptoms and impulsivity during bipolar depressive episodes. Bipolar Disord 2007;9(3):206-12
31. Frye MA, Helleman G, McElroy SL, Altshuler LL, Black DO, Keck PE Jr, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 2009;166(2):164-72
32. Frye MA, Eudicone J, Pikalov A, McQuade RD, Marcus RN, Carlson BX. Aripiprazole effi cacy in irritability and disruptive- aggressive symptoms: young mania rating scale line analysis from two, randomized, double-blind, placebo-controlled trials. J Clin Psychopharmacol 2008;28(2):243-5